

# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	5	6.0	83.8	(27.0-195.6)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	2.4	253.2	(92.5-551.2)	Female	0	0.6	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male 1 0.5 nc (nc-nc)				
Male	0	0.4	nc	(nc-nc)	Female 0 0.4 nc (nc-nc)				
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male 5 6.6 75.4 (24.3-176.0)				
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male 0 0.4 nc (nc-nc)				
<u>Kidney &amp; Renal Pelvis</u>					Female 0 0.2 nc (nc-nc)				
Male	0	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.4	nc	(nc-nc)	Male 1 0.3 nc (nc-nc)				
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male 0 0.2 nc (nc-nc)				
Female	0	0.1	nc	(nc-nc)	Female 0 0.6 nc (nc-nc)				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female 2 1.2 nc (nc-nc)				
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male 21 21.7 97.0 (60.0-148.2)				
Male	1	0.3	nc	(nc-nc)	Female 15 18.6 80.6 (45.1-132.9)				
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	3.0	nc	(nc-nc)					
Female	3	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.8	nc	(nc-nc)	Male	5	3.0	166.7	(53.7-388.9)
Female	0	1.5	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	24	19.5	123.0	(78.8-183.0)	Female	2	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	7.5	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
Female	7	6.3	111.6	(44.7-229.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	17	19.9	85.3	(49.7-136.6)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.2	nc	(nc-nc)	Female	7	3.8	183.5	(73.5-378.2)
Female	2	1.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	3	1.7	nc	(nc-nc)	Male	6	9.2	65.3	(23.8-142.1)
Female	1	1.3	nc	(nc-nc)	Female	18	7.5	240.3	(142.3-379.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	46	41.0	112.1	(82.1-149.5)	Male	21	22.1	95.0	(58.8-145.2)
Female	16	16.5	96.9	(55.3-157.3)	Female	28	20.1	139.0	(92.3-200.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	7.8	nc	(nc-nc)	Male	9	5.9	151.9	(69.3-288.4)
Female	3	7.6	nc	(nc-nc)	Female	6	5.4	111.0	(40.5-241.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	22	21.2	103.7	(65.0-157.0)
Female	189	168.0	112.5	(97.0-129.7)	Female	30	21.6	138.9	(93.7-198.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	7.6	92.2	(36.9-189.9)	Male	17	15.2	112.2	(65.3-179.6)
					Female	13	8.5	152.6	(81.1-260.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	69	62.0	111.4	(86.6-140.9)	Female	14	18.0	78.0	(42.6-130.8)
Female	73	68.5	106.6	(83.5-134.0)					
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	10.1	99.5	(47.6-183.0)	Male	18	11.6	154.5	(91.5-244.2)
Female	2	3.3	nc	(nc-nc)	Female	16	14.5	110.6	(63.2-179.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	164	162.3	101.1	(86.2-117.8)
Female	3	3.4	nc	(nc-nc)					
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Stomach</u></b>				
Male	21	16.7	125.8	(77.9-192.3)	Male	14	10.5	133.7	(73.0-224.3)
Female	5	12.0	41.7	(13.4-97.2)	Female	13	7.3	178.9	(95.2-306.0)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	9	7.0	128.8	(58.8-244.5)	Male	8	6.7	119.2	(51.3-234.8)
Female	3	2.1	nc	(nc-nc)					
<b><u>Leukemia</u></b>					<b><u>Thyroid</u></b>				
Male	17	12.9	131.6	(76.6-210.6)	Male	4	4.5	nc	(nc-nc)
Female	17	12.1	141.0	(82.1-225.7)	Female	10	16.4	61.1	(29.3-112.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	7.8	77.2	(28.2-168.0)	Female	29	33.8	85.8	(57.4-123.2)
Female	2	3.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	101	77.5	130.4	(106.2-158.4)	Male	595	544.6	109.3	(100.7-118.4)
Female	102	78.1	130.7	(106.5-158.6)	Female	645	570.9	113.0	(104.4-122.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.9	113.2	(51.7-214.9)	Male	1	4.6	nc	(nc-nc)
Female	9	2.7	331.5	(151.3-629.3)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
Female	27	31.2	86.4	(56.9-125.8)	Female	4	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.4	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	22	12.3	179.0	(112.1-271.0)	Female	4	3.2	nc	(nc-nc)
Female	8	10.9	73.5	(31.6-144.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	2.3	213.0	(68.7-497.2)
Male	7	2.1	335.0	(134.2-690.2)	Female	2	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	35	34.3	102.2	(71.2-142.1)
Male	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	1.1	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	5	2.1	235.9	(76.0-550.5)	Male	1	1.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.6	nc	(nc-nc)	Female	5	6.5	77.5	(25.0-180.8)
Female	2	2.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	135	111.2	121.4	(101.8-143.7)
Male	2	1.6	nc	(nc-nc)	Female	111	100.1	110.8	(91.2-133.5)
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	23	15.5	148.2	(93.9-222.3)					
Female	23	13.5	170.0	(107.7-255.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	7	6.1	115.0	(46.1-237.0)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	17	19.4	87.5	(50.9-140.1)
Male	0	0.3	nc	(nc-nc)	Female	8	11.4	70.2	(30.2-138.3)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	5	2.9	172.9	(55.7-403.6)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	22.6	128.5	(86.1-184.6)	Male	26	12.1	215.6	(140.8-316.0)
Female	13	7.8	167.2	(89.0-286.0)	Female	20	9.6	207.5	(126.7-320.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.3	162.9	(65.2-335.6)	Male	8	3.3	243.1	(104.7-479.0)
Female	6	3.7	161.6	(59.0-351.8)	Female	1	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	15	11.6	129.8	(72.6-214.1)
Female	99	85.1	116.3	(94.5-141.6)	Female	7	10.2	68.3	(27.4-140.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.7	nc	(nc-nc)	Male	5	8.7	57.7	(18.6-134.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	38	34.3	110.9	(78.5-152.3)	Female	11	8.9	124.0	(61.8-221.8)
Female	39	31.8	122.6	(87.2-167.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	6.5	92.5	(33.8-201.3)
Male	5	5.6	88.6	(28.5-206.7)	Female	9	6.7	134.2	(61.3-254.8)
Female	0	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	118	91.4	129.2	(106.9-154.7)
Male	1	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	3.3	nc	(nc-nc)
Male	9	9.4	95.5	(43.6-181.3)	<b><u>Testis</u></b>				
Female	3	5.9	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	5	7.8	64.4	(20.8-150.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	7.1	155.1	(77.3-277.5)	Female	10	17.1	58.4	(27.9-107.3)
Female	14	5.7	245.4	(134.0-411.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	342	301.6	113.4	(101.7-126.1)
Male	2	4.4	nc	(nc-nc)	Female	302	277.4	108.9	(96.9-121.9)
Female	0	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	33	43.2	76.4	(52.6-107.3)					
Female	30	37.6	79.7	(53.8-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	34.7	138.2	(101.9-183.2)	Male	16	17.7	90.5	(51.7-147.0)
Female	15	12.6	119.4	(66.8-197.0)	Female	9	14.2	63.4	(28.9-120.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.0	117.1	(46.9-241.4)	Male	2	5.0	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)	Female	1	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	22	17.1	129.0	(80.8-195.3)
Female	117	126.5	92.5	(76.5-110.8)	Female	16	16.0	99.7	(57.0-162.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	5.3	95.0	(30.6-221.6)	Male	14	12.5	111.6	(60.9-187.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	55	52.2	105.4	(79.4-137.2)	Female	7	13.4	52.3	(20.9-107.7)
Female	47	51.2	91.9	(67.5-122.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	9.9	101.3	(48.5-186.3)
Male	11	8.5	129.1	(64.3-231.0)	Female	4	10.9	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	138	140.1	98.5	(82.7-116.4)
Male	1	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	9	8.8	102.6	(46.8-194.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	5.3	93.7	(30.2-218.8)
Male	12	13.9	86.3	(44.5-150.8)	<b><u>Testis</u></b>				
Female	9	9.1	98.8	(45.1-187.5)	Male	8	3.9	203.6	(87.7-401.2)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	8	5.9	134.7	(58.0-265.4)	Male	4	3.3	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	12	10.7	111.8	(57.7-195.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	10.4	115.8	(59.8-202.4)	Female	34	26.1	130.2	(90.2-182.0)
Female	9	8.7	103.5	(47.2-196.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	500	456.1	109.6	(100.2-119.7)
Male	10	6.4	155.4	(74.4-285.9)	Female	413	426.6	96.8	(87.7-106.6)
Female	2	2.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	76	66.0	115.1	(90.7-144.0)					
Female	66	60.4	109.2	(84.5-139.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.3	nc	(nc-nc)	Female	3	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.2	nc	(nc-nc)	Female	3	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	5	10.7	46.6	(15.0-108.8)
Female	3	1.0	nc	(nc-nc)	Female	11	8.1	135.1	(67.4-241.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	21.3	51.5	(25.7-92.2)	Male	17	11.4	149.8	(87.2-239.8)
Female	6	7.6	78.9	(28.8-171.8)	Female	14	9.1	154.1	(84.2-258.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.9	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	9	10.8	83.3	(38.0-158.2)
Female	85	81.1	104.8	(83.7-129.6)	Female	8	9.9	81.2	(35.0-160.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.5	nc	(nc-nc)	Male	11	8.3	132.6	(66.1-237.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	26	32.4	80.2	(52.4-117.5)	Female	7	8.5	82.5	(33.1-170.0)
Female	34	30.9	110.0	(76.2-153.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	6.2	97.5	(35.6-212.3)
Male	5	5.4	92.1	(29.7-214.9)	Female	8	6.5	122.4	(52.7-241.1)
Female	2	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	78	90.0	86.6	(68.5-108.1)
Male	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.2	nc	(nc-nc)
Male	6	9.0	66.5	(24.3-144.7)	<b><u>Testis</u></b>				
Female	2	5.7	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.8	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	5	7.1	70.1	(22.6-163.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	6.6	76.0	(24.5-177.4)	Female	19	16.6	114.4	(68.8-178.7)
Female	7	5.5	128.3	(51.4-264.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	259	289.0	89.6	(79.0-101.2)
Male	3	4.2	nc	(nc-nc)	Female	263	266.6	98.7	(87.1-111.3)
Female	1	1.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	47	41.4	113.5	(83.4-150.9)					
Female	35	36.8	95.2	(66.3-132.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	15.6	108.7	(63.3-174.1)	Male	8	8.5	94.4	(40.6-185.9)
Female	3	5.0	nc	(nc-nc)	Female	8	6.5	123.9	(53.4-244.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	3	8.1	nc	(nc-nc)
Female	73	56.5	129.2	(101.3-162.5)	Female	3	6.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	5	6.2	81.1	(26.1-189.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	23	23.8	96.5	(61.1-144.8)	Female	4	5.9	nc	(nc-nc)
Female	11	20.3	54.1	(27.0-96.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	4.5	nc	(nc-nc)
Male	5	4.0	125.6	(40.5-293.1)	Female	2	4.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	65	65.3	99.5	(76.8-126.8)
Male	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	13	4.0	327.7	(174.3-560.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.1	nc	(nc-nc)
Male	7	6.7	105.2	(42.2-216.8)	<b><u>Testis</u></b>				
Female	1	3.9	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	4.9	nc	(nc-nc)	Female	9	11.4	78.8	(36.0-149.6)
Female	5	3.7	136.4	(43.9-318.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	202	212.2	95.2	(82.5-109.3)
Male	1	3.1	nc	(nc-nc)	Female	169	182.3	92.7	(79.3-107.8)
Female	2	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	28	30.3	92.5	(61.5-133.7)					
Female	20	24.8	80.6	(49.2-124.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	17.3	92.7	(52.9-150.5)	Male	14	10.0	140.3	(76.7-235.5)
Female	5	5.8	86.3	(27.8-201.3)	Female	13	7.9	163.5	(87.0-279.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.6	138.3	(44.6-322.7)	Male	4	2.6	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	18	9.3	192.8	(114.2-304.7)
Female	93	70.3	132.2	(106.7-162.0)	Female	11	7.9	139.3	(69.4-249.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.2	nc	(nc-nc)	Male	8	7.4	107.6	(46.3-212.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	26.8	89.6	(57.4-133.4)	Female	7	7.2	97.2	(38.9-200.3)
Female	23	23.7	97.1	(61.6-145.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	5.1	176.6	(80.6-335.2)
Male	4	4.6	nc	(nc-nc)	Female	8	4.9	161.7	(69.6-318.6)
Female	2	1.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	69	73.5	93.9	(73.0-118.8)
Male	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	7	4.5	156.3	(62.6-322.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	2.4	204.4	(65.9-477.0)
Male	3	7.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	6	4.6	130.2	(47.5-283.4)	Male	4	2.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	3.2	nc	(nc-nc)	Male	5	2.1	241.8	(77.9-564.3)
Female	0	0.8	nc	(nc-nc)	Female	9	6.7	134.0	(61.1-254.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	5.7	nc	(nc-nc)	Female	18	14.0	128.4	(76.1-203.0)
Female	3	4.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	242	240.8	100.5	(88.2-114.0)
Male	2	3.7	nc	(nc-nc)	Female	249	219.8	113.3	(99.7-128.3)
Female	1	1.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	30	33.6	89.2	(60.2-127.4)					
Female	24	28.6	83.9	(53.7-124.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	4.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	9	15.2	59.2	(27.0-112.3)	Female	1	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	6.6	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	3	5.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	15	18.1	82.7	(46.3-136.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	1.8	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	6	8.4	71.5	(26.1-155.5)
Female	1	1.0	nc	(nc-nc)	Female	4	7.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	7	11.1	63.1	(25.3-130.0)	Female	1	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	4.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	12	5.1	235.9	(121.8-412.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	14	11.4	122.8	(67.1-206.1)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.2	nc	(nc-nc)	Female	5	2.2	227.5	(73.3-530.8)
Female	1	0.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	5	5.4	93.0	(30.0-217.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.6	130.6	(47.7-284.3)	Male	6	2.6	231.2	(84.4-503.3)
Female	0	1.4	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	18	17.6	102.2	(60.6-161.6)	Female	2	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	7.1	84.2	(30.8-183.4)	Female	3	1.8	nc	(nc-nc)
Female	5	5.6	89.7	(28.9-209.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	1.4	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	23	20.2	114.0	(72.2-171.0)
Male	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.6	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	1.5	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	58	64.4	90.1	(68.4-116.5)
Male	0	1.0	nc	(nc-nc)	Female	43	53.8	79.9	(57.8-107.6)
Female	0	0.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	9.1	nc	(nc-nc)					
Female	3	7.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	5.4	129.4	(51.9-266.7)	Male	3	3.6	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	24	20.0	119.9	(76.8-178.5)	Female	2	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	8.5	140.6	(72.6-245.7)	Female	2	2.1	nc	(nc-nc)
Female	6	6.8	88.1	(32.2-191.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	1.6	nc	(nc-nc)
Male	5	1.5	341.7	(110.1-797.5)	Female	0	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	17	23.4	72.8	(42.4-116.5)
Male	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.7	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	4	1.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.9	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	91	79.7	114.2	(92.0-140.3)
Male	1	1.2	nc	(nc-nc)	Female	74	63.7	116.2	(91.3-145.9)
Female	0	0.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	16	10.7	148.9	(85.0-241.8)					
Female	16	8.4	190.8	(109.0-309.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	32.9	94.3	(64.0-133.8)	Male	14	18.0	77.7	(42.4-130.3)
Female	10	12.0	83.5	(40.0-153.6)	Female	11	14.9	73.9	(36.8-132.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	6.4	186.3	(96.2-325.5)	Male	3	4.8	nc	(nc-nc)
Female	4	5.7	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	20	17.2	116.5	(71.1-179.9)
Female	135	126.2	107.0	(89.7-126.6)	Female	15	15.7	95.3	(53.3-157.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.8	103.9	(38.0-226.3)	Male	7	12.6	55.6	(22.3-114.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	35	50.0	70.0	(48.8-97.4)	Female	9	13.3	67.6	(30.8-128.3)
Female	48	49.3	97.4	(71.8-129.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	9.4	95.3	(43.5-181.0)
Male	1	8.2	nc	(nc-nc)	Female	13	10.4	125.0	(66.5-213.7)
Female	0	2.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	101	131.5	76.8	(62.6-93.3)
Male	2	2.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	6	2.3	262.6	(95.9-571.5)	Male	10	8.4	118.6	(56.8-218.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	5.2	nc	(nc-nc)
Male	16	13.8	116.3	(66.4-188.8)	<b><u>Testis</u></b>				
Female	7	8.9	78.8	(31.6-162.4)	Male	7	5.0	139.1	(55.7-286.6)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	5.7	nc	(nc-nc)	Male	7	3.7	188.8	(75.6-389.1)
Female	1	1.6	nc	(nc-nc)	Female	11	12.2	90.3	(45.0-161.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	10.5	57.0	(20.8-124.1)	Female	22	25.4	86.7	(54.3-131.3)
Female	7	8.9	78.6	(31.5-162.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	367	440.6	83.3	(75.0-92.3)
Male	9	6.4	140.6	(64.2-267.0)	Female	389	421.0	92.4	(83.4-102.1)
Female	1	2.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	50	62.4	80.1	(59.5-105.6)					
Female	49	57.2	85.7	(63.4-113.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	9	6.2	145.4	(66.3-276.0)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	2.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	6	5.6	107.8	(39.3-234.5)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	16	19.1	83.8	(47.9-136.1)
Male	0	0.3	nc	(nc-nc)	Female	17	17.6	96.6	(56.3-154.7)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	2.5	nc	(nc-nc)					
Female	1	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	27.1	114.5	(77.8-162.5)	Male	8	13.3	60.3	(26.0-118.8)
Female	5	10.4	48.3	(15.6-112.7)	Female	8	10.7	75.1	(32.3-148.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.4	136.6	(49.9-297.3)	Male	2	3.8	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	8	12.9	61.9	(26.7-122.0)
Female	103	97.4	105.7	(86.3-128.2)	Female	23	12.9	178.4	(113.1-267.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.8	nc	(nc-nc)	Male	8	9.4	85.3	(36.7-168.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	37	40.4	91.7	(64.5-126.3)	Female	8	10.5	76.6	(33.0-150.8)
Female	42	42.6	98.5	(71.0-133.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	15	7.6	196.9	(110.1-324.7)
Male	9	6.5	137.9	(62.9-261.7)	Female	9	9.1	99.0	(45.2-188.0)
Female	2	2.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	114	107.6	105.9	(87.4-127.2)
Male	4	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.4	nc	(nc-nc)	Male	11	6.8	162.9	(81.2-291.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	4.5	nc	(nc-nc)
Male	12	10.6	113.7	(58.7-198.7)	<b><u>Testis</u></b>				
Female	9	7.2	124.2	(56.7-235.9)	Male	1	2.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	4.5	110.3	(35.5-257.3)	Male	2	2.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	6	7.5	80.5	(29.4-175.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	7.9	114.3	(52.2-217.1)	Female	20	20.2	99.1	(60.5-153.1)
Female	4	7.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	365	349.6	104.4	(94.0-115.7)
Male	3	4.9	nc	(nc-nc)	Female	314	337.8	93.0	(83.0-103.8)
Female	0	2.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	56	51.3	109.1	(82.4-141.6)					
Female	40	48.9	81.8	(58.4-111.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	55	57.9	94.9	(71.5-123.6)	Male	21	34.8	60.3	(37.3-92.2)
Female	23	24.4	94.3	(59.8-141.5)	Female	19	33.6	56.5	(34.0-88.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	12.9	92.7	(47.8-161.9)	Male	5	8.5	58.9	(19.0-137.6)
Female	14	12.1	115.7	(63.2-194.2)	Female	8	7.9	100.7	(43.4-198.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	31	33.1	93.7	(63.7-133.0)
Female	221	250.7	88.2	(76.9-100.6)	Female	34	33.0	103.0	(71.3-143.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	11	12.9	85.4	(42.6-152.8)	Male	26	22.4	116.1	(75.8-170.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	95	88.4	107.5	(86.9-131.4)	Female	15	27.2	55.2	(30.9-91.0)
Female	95	101.0	94.1	(76.1-115.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	15	16.5	90.9	(50.8-149.9)
Male	23	14.3	160.5	(101.7-240.8)	Female	17	21.3	79.9	(46.5-128.0)
Female	0	4.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	181	229.0	79.0	(67.9-91.4)
Male	5	7.9	63.4	(20.4-147.8)	<b><u>Stomach</u></b>				
Female	7	7.2	97.4	(39.0-200.7)	Male	17	15.1	112.9	(65.7-180.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	19	10.8	175.3	(105.5-273.8)
Male	26	24.4	106.6	(69.6-156.1)	<b><u>Testis</u></b>				
Female	12	17.9	67.2	(34.7-117.4)	Male	24	16.6	144.3	(92.4-214.7)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	14	10.0	140.2	(76.6-235.2)	Male	7	8.2	85.2	(34.1-175.5)
Female	0	3.1	nc	(nc-nc)	Female	37	30.1	123.1	(86.6-169.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	19	19.9	95.3	(57.3-148.8)	Female	46	50.0	91.9	(67.3-122.6)
Female	24	18.5	129.5	(83.0-192.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	768	798.2	96.2	(89.5-103.3)
Male	22	11.3	194.2	(121.6-294.0)	Female	831	864.0	96.2	(89.8-103.0)
Female	10	5.0	199.7	(95.6-367.4)					
<b><u>Lung and Bronchus</u></b>									
Male	114	109.6	104.0	(85.8-124.9)					
Female	123	114.8	107.1	(89.0-127.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	21.3	117.5	(76.0-173.5)	Male	14	10.5	133.0	(72.6-223.1)
Female	8	8.2	97.5	(42.0-192.0)	Female	14	9.2	152.7	(83.4-256.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	3.5	198.0	(79.3-408.0)	Male	2	3.0	nc	(nc-nc)
Female	5	3.5	141.0	(45.5-329.1)	Female	2	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	11	10.3	107.2	(53.4-191.7)
Female	90	78.9	114.1	(91.7-140.2)	Female	13	10.5	123.6	(65.8-211.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	6	7.4	81.6	(29.8-177.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	29	31.8	91.3	(61.1-131.1)	Female	9	8.6	105.2	(48.0-199.7)
Female	31	34.0	91.2	(62.0-129.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	6.0	116.9	(46.8-240.8)
Male	7	5.1	137.5	(55.1-283.3)	Female	12	7.2	166.3	(85.9-290.6)
Female	0	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	79	82.4	95.8	(75.9-119.4)
Male	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	6	5.4	112.1	(40.9-243.9)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	3.6	nc	(nc-nc)
Male	9	8.3	109.0	(49.8-207.0)	<b><u>Testis</u></b>				
Female	3	5.8	nc	(nc-nc)	Male	9	2.2	406.9	(185.7-772.5)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	7.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	6.3	nc	(nc-nc)	Female	15	16.1	93.5	(52.3-154.1)
Female	6	5.8	102.8	(37.5-223.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	283	273.0	103.7	(91.9-116.5)
Male	2	3.8	nc	(nc-nc)	Female	259	274.3	94.4	(83.3-106.7)
Female	1	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	40	39.9	100.2	(71.6-136.5)					
Female	26	38.7	67.1	(43.8-98.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	5.0	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	21	21.1	99.4	(61.5-152.0)	Female	1	2.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	7.8	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Female	6	7.0	85.8	(31.3-186.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	22	21.3	103.1	(64.6-156.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.3	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	3	1.7	nc	(nc-nc)	Male	9	9.7	92.8	(42.3-176.2)
Female	2	1.3	nc	(nc-nc)	Female	11	8.5	129.7	(64.6-232.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.0	127.9	(58.4-242.9)	Male	5	4.4	114.0	(36.8-266.1)
Female	1	2.2	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.7	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.1	123.4	(39.8-288.1)
Female	52	29.1	178.4	(133.2-234.0)	Female	1	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	11.0	54.4	(19.9-118.4)	Female	3	3.0	nc	(nc-nc)
Female	7	9.0	78.1	(31.3-160.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	28	30.8	90.8	(60.3-131.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	3.3	149.3	(48.1-348.3)	Female	4	5.8	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	7	13.9	50.5	(20.2-104.0)
Female	3	1.9	nc	(nc-nc)	Female	4	11.1	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	18.8	111.6	(69.0-170.6)	Male	10	9.7	102.9	(49.3-189.2)
Female	3	7.6	nc	(nc-nc)	Female	4	8.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	3.5	201.9	(80.9-416.1)	Male	1	2.7	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	5	9.5	52.8	(17.0-123.2)
Female	59	71.6	82.4	(62.7-106.3)	Female	10	9.6	103.9	(49.7-191.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.1	162.8	(52.5-380.0)	Male	8	6.6	120.5	(51.9-237.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	26	28.2	92.1	(60.1-134.9)	Female	11	7.7	142.1	(70.9-254.3)
Female	33	31.8	103.9	(71.5-145.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	4.5	nc	(nc-nc)	Male	63	71.0	88.7	(68.2-113.5)
Female	0	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	7.4	95.0	(38.1-195.8)	Female	17	14.3	118.7	(69.1-190.0)
Female	2	5.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	8	3.1	259.3	(111.6-511.0)	Male	1	3.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	4	5.9	nc	(nc-nc)	Male	42	34.7	121.0	(87.2-163.5)
Female	4	5.5	nc	(nc-nc)	Female	26	34.8	74.7	(48.8-109.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	8.7	104.0	(47.5-197.5)	Male	7	5.0	141.2	(56.6-290.9)
Female	3	2.9	nc	(nc-nc)	Female	7	3.9	179.4	(71.9-369.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.7	149.2	(59.8-307.3)
Female	35	33.2	105.5	(73.5-146.7)	Female	4	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	13.3	67.8	(31.0-128.8)	Female	3	3.4	nc	(nc-nc)
Female	17	11.9	143.0	(83.3-229.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	2.5	199.2	(64.2-464.9)
Male	2	2.2	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	31	34.7	89.2	(60.6-126.7)
Male	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	5	2.2	223.8	(72.1-522.3)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.2	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.8	nc	(nc-nc)	Female	5	6.6	75.5	(24.3-176.2)
Female	0	2.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	121	117.7	102.8	(85.3-122.8)
Male	2	1.8	nc	(nc-nc)	Female	99	107.1	92.4	(75.1-112.5)
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	23	16.5	139.8	(88.6-209.8)					
Female	13	14.3	90.9	(48.4-155.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	12.3	48.6	(17.7-105.8)	Male	5	6.8	73.2	(23.6-170.8)
Female	6	4.1	147.7	(53.9-321.6)	Female	5	5.3	94.6	(30.5-220.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	10	6.5	154.1	(73.8-283.4)
Female	44	45.1	97.6	(70.9-131.1)	Female	8	5.4	146.8	(63.2-289.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	18.9	79.5	(44.4-131.1)	Female	6	4.7	127.1	(46.4-276.6)
Female	15	16.5	90.8	(50.8-149.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	27	50.7	53.2	(35.1-77.5)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	5.3	nc	(nc-nc)	Female	12	9.2	131.1	(67.7-229.1)
Female	4	3.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	3.9	nc	(nc-nc)	Male	22	23.7	92.8	(58.2-140.6)
Female	6	3.0	198.1	(72.3-431.1)	Female	26	20.0	130.1	(85.0-190.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	111	137.4	80.8	(66.5-97.3)	Male	44	73.1	60.2	(43.8-80.9)
Female	40	54.5	73.4	(52.5-100.0)	Female	17	66.6	25.5	(14.9-40.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	20	27.4	73.0	(44.6-112.7)	Male	18	19.8	91.1	(54.0-144.0)
Female	24	26.3	91.3	(58.4-135.8)	Female	16	17.8	89.9	(51.4-146.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	4.2	nc	(nc-nc)	Male	64	71.1	90.0	(69.3-115.0)
Female	524	554.6	94.5	(86.6-102.9)	Female	67	71.6	93.6	(72.5-118.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	36	25.0	143.8	(100.7-199.0)	Male	57	49.9	114.2	(86.5-148.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	191	206.9	92.3	(79.7-106.4)	Female	45	59.5	75.7	(55.2-101.3)
Female	210	224.6	93.5	(81.3-107.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	31	38.9	79.6	(54.1-113.0)
Male	42	33.3	126.3	(91.0-170.7)	Female	43	47.5	90.4	(65.4-121.8)
Female	12	10.8	111.6	(57.6-195.0)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	482	532.6	90.5	(82.6-99.0)
Male	7	12.7	55.2	(22.1-113.7)	<b><u>Stomach</u></b>				
Female	11	12.1	91.1	(45.4-163.0)	Male	45	35.0	128.6	(93.8-172.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	32	23.7	135.0	(92.4-190.7)
Male	49	55.3	88.6	(65.5-117.1)	<b><u>Testis</u></b>				
Female	47	40.0	117.4	(86.3-156.2)	Male	26	22.3	116.6	(76.2-170.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	35	23.1	151.8	(105.7-211.2)	Male	5	14.9	33.6	(10.8-78.5)
Female	6	7.0	85.3	(31.1-185.6)	Female	44	54.4	80.9	(58.8-108.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	34	44.9	75.7	(52.4-105.7)	Female	133	111.9	118.9	(99.5-140.9)
Female	40	41.3	96.9	(69.2-132.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	1626	1811.2	89.8	(85.5-94.2)
Male	28	25.7	109.1	(72.5-157.6)	Female	1748	1889.9	92.5	(88.2-96.9)
Female	9	11.0	81.8	(37.3-155.3)					
<b><u>Lung and Bronchus</u></b>									
Male	227	257.6	88.1	(77.0-100.3)					
Female	242	259.1	93.4	(82.0-105.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	6.7	88.9	(32.5-193.5)	Male	2	4.1	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.8	159.0	(58.1-346.0)
Female	20	26.3	76.2	(46.5-117.6)	Female	3	2.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	10	10.6	94.7	(45.3-174.1)	Female	3	2.7	nc	(nc-nc)
Female	3	8.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.0	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	35	28.7	122.1	(85.0-169.8)
Male	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.8	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.3	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	92	95.3	96.5	(77.8-118.3)
Male	0	1.5	nc	(nc-nc)	Female	68	80.2	84.8	(65.8-107.5)
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	13.2	45.5	(16.6-99.0)					
Female	9	10.0	89.7	(40.9-170.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	4.1	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	11	13.4	81.9	(40.8-146.6)	Female	2	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	6.1	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
Female	5	5.5	90.8	(29.3-211.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	14	15.8	88.5	(48.3-148.5)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	5	7.7	65.0	(20.9-151.7)
Female	0	0.9	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	29.1	106.6	(72.4-151.4)	Male	9	14.7	61.4	(28.0-116.6)
Female	13	11.3	114.7	(61.0-196.2)	Female	13	12.3	106.0	(56.4-181.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.9	101.0	(32.6-235.8)	Male	4	4.1	nc	(nc-nc)
Female	5	4.7	106.6	(34.3-248.7)	Female	4	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	9	14.2	63.4	(28.9-120.3)
Female	119	107.9	110.3	(91.4-132.0)	Female	12	14.3	84.1	(43.4-146.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.5	111.6	(36.0-260.5)	Male	11	10.2	107.7	(53.7-192.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	49	43.5	112.7	(83.4-149.0)	Female	18	11.6	155.5	(92.1-245.7)
Female	57	47.1	121.0	(91.6-156.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	8.2	122.2	(58.5-224.7)
Male	7	7.0	100.2	(40.1-206.4)	Female	19	10.0	190.1	(114.4-296.9)
Female	3	2.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	133	113.1	117.6	(98.5-139.4)
Male	2	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	3	7.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	6	5.0	119.1	(43.5-259.2)
Male	14	11.4	123.3	(67.4-206.9)	<b><u>Testis</u></b>				
Female	9	7.9	113.5	(51.8-215.5)	Male	3	3.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	4.8	124.2	(45.4-270.4)	Male	2	2.8	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	11	9.1	121.0	(60.3-216.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	8.7	103.8	(47.4-197.1)	Female	9	21.8	41.3	(18.8-78.3)
Female	6	7.9	75.7	(27.6-164.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	390	375.2	103.9	(93.9-114.8)
Male	3	5.3	nc	(nc-nc)	Female	408	374.0	109.1	(98.8-120.2)
Female	0	2.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	56	54.3	103.2	(77.9-134.0)					
Female	65	52.7	123.3	(95.2-157.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	31.0	109.8	(76.0-153.4)	Male	24	16.6	144.4	(92.5-214.9)
Female	8	11.8	67.5	(29.1-133.1)	Female	21	14.1	149.2	(92.3-228.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	5.8	nc	(nc-nc)	Male	5	4.5	110.7	(35.7-258.3)
Female	4	5.3	nc	(nc-nc)	Female	9	3.9	232.4	(106.0-441.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	14	15.9	88.1	(48.1-147.8)
Female	115	122.7	93.7	(77.4-112.5)	Female	13	15.3	84.8	(45.1-145.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	5.3	188.8	(90.4-347.3)	Male	13	11.9	109.6	(58.3-187.5)
					Female	6	6.1	97.7	(35.7-212.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	45	47.1	95.6	(69.7-127.9)	Female	13	13.0	100.3	(53.3-171.5)
Female	43	48.4	88.9	(64.3-119.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	8.9	67.3	(24.6-146.5)
Male	12	7.8	154.5	(79.7-269.9)	Female	14	10.2	136.6	(74.6-229.2)
Female	2	2.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	144	126.7	113.6	(95.8-133.8)
Male	3	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	8	7.9	101.4	(43.7-199.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	5.1	nc	(nc-nc)
Male	9	12.9	69.7	(31.8-132.3)	<b><u>Testis</u></b>				
Female	8	8.7	92.0	(39.6-181.4)	Male	3	4.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	5.5	nc	(nc-nc)	Male	6	3.3	180.6	(65.9-393.0)
Female	1	1.6	nc	(nc-nc)	Female	10	11.0	90.6	(43.4-166.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	9.6	83.0	(35.7-163.5)	Female	23	25.2	91.4	(57.9-137.2)
Female	8	8.4	95.2	(41.0-187.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	434	415.9	104.3	(94.8-114.6)
Male	4	6.0	nc	(nc-nc)	Female	419	410.1	102.2	(92.6-112.4)
Female	1	2.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	59	59.3	99.4	(75.7-128.3)					
Female	66	56.9	116.0	(89.7-147.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.9	nc	(nc-nc)	Male	7	3.1	222.8	(89.3-459.2)
Female	2	1.6	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	2.9	209.7	(76.6-456.5)
Female	18	22.0	81.7	(48.4-129.2)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	7.8	64.1	(20.7-149.7)	Female	0	2.2	nc	(nc-nc)
Female	7	6.6	105.3	(42.2-217.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	22.9	82.9	(49.9-129.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	0	2.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	8	9.9	81.0	(34.9-159.7)	Male	57	73.2	77.8	(58.9-100.9)
Female	5	8.3	60.3	(19.4-140.8)	Female	48	66.5	72.1	(53.2-95.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.1	120.5	(60.1-215.6)	Male	1	4.9	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.7	170.5	(73.4-335.9)
Female	23	32.8	70.1	(44.4-105.1)	Female	4	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	14	13.9	100.6	(54.9-168.8)	Female	5	3.4	146.3	(47.1-341.3)
Female	11	12.1	90.8	(45.3-162.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	2.6	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	29	37.3	77.8	(52.1-111.7)
Male	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.2	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	2.9	210.0	(76.7-457.1)	Female	9	6.6	135.4	(61.8-257.0)
Female	1	2.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	115	122.8	93.7	(77.3-112.4)
Male	0	1.8	nc	(nc-nc)	Female	92	107.0	86.0	(69.3-105.4)
Female	1	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	17.5	125.7	(78.8-190.4)					
Female	15	14.6	102.4	(57.3-169.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	15.4	117.1	(69.4-185.1)	Male	14	9.2	152.3	(83.2-255.6)
Female	7	5.0	140.8	(56.4-290.0)	Female	12	7.2	165.6	(85.5-289.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	2.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	16	8.5	187.8	(107.3-305.0)
Female	85	63.4	134.0	(107.1-165.7)	Female	6	6.9	87.1	(31.8-189.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.0	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	25	24.0	104.2	(67.4-153.8)	Female	6	6.5	92.9	(33.9-202.1)
Female	25	20.2	124.0	(80.2-183.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	4.6	174.8	(75.3-344.5)
Male	2	4.2	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	73	68.5	106.5	(83.5-134.0)
Male	0	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	8	4.0	200.7	(86.4-395.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.1	nc	(nc-nc)
Male	4	7.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	4.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	7	6.3	110.6	(44.3-227.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	5.2	nc	(nc-nc)	Female	10	12.8	78.3	(37.5-144.0)
Female	2	4.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	226	220.5	102.5	(89.6-116.8)
Male	2	3.4	nc	(nc-nc)	Female	218	194.8	111.9	(97.6-127.8)
Female	0	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	30.5	72.2	(45.2-109.3)					
Female	23	24.7	93.1	(59.0-139.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	13	10.7	121.2	(64.5-207.3)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	3.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	6	4.0	148.7	(54.3-323.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	9.8	132.8	(70.6-227.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	0	1.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	4.8	nc	(nc-nc)	Male	27	34.9	77.4	(51.0-112.6)
Female	2	4.5	nc	(nc-nc)	Female	32	35.9	89.2	(61.0-126.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.0	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	5	3.3	150.9	(48.6-352.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.0	125.3	(40.4-292.5)
Female	19	27.3	69.5	(41.8-108.5)	Female	5	3.0	168.4	(54.3-392.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	14	11.0	127.7	(69.7-214.2)	Female	4	2.8	nc	(nc-nc)
Female	6	8.3	72.1	(26.3-156.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	23	30.1	76.5	(48.5-114.7)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	3.3	152.6	(49.2-356.2)	Female	5	5.4	91.9	(29.6-214.3)
Female	3	1.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	5	2.4	207.9	(67.0-485.1)	Male	7	13.6	51.5	(20.6-106.2)
Female	3	1.7	nc	(nc-nc)	Female	11	10.5	105.2	(52.4-188.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	19.1	105.0	(64.1-162.1)	Male	26	9.5	272.6	(178.0-399.4)
Female	10	7.3	136.4	(65.3-250.9)	Female	11	8.0	137.2	(68.4-245.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	5	2.7	183.7	(59.2-428.8)
Female	3	3.1	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.3	108.0	(51.7-198.7)
Female	82	71.3	115.0	(91.4-142.7)	Female	13	9.3	140.4	(74.7-240.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.0	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	20	28.5	70.1	(42.8-108.3)	Female	11	7.6	144.5	(72.0-258.6)
Female	32	31.0	103.2	(70.6-145.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	5.4	167.2	(76.3-317.4)
Male	3	4.5	nc	(nc-nc)	Female	7	6.5	107.5	(43.1-221.4)
Female	0	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	67	71.6	93.6	(72.5-118.8)
Male	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	0	4.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	3.3	nc	(nc-nc)
Male	9	7.3	122.5	(55.9-232.5)	<b><u>Testis</u></b>				
Female	8	5.1	156.1	(67.2-307.6)	Male	1	2.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	7	6.0	117.2	(47.0-241.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	5.7	141.1	(60.8-278.1)	Female	11	14.2	77.5	(38.6-138.7)
Female	11	5.2	209.6	(104.5-375.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	234	242.1	96.6	(84.7-109.9)
Male	3	3.4	nc	(nc-nc)	Female	279	244.5	114.1	(101.1-128.3)
Female	0	1.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	24	34.8	69.0	(44.2-102.7)					
Female	32	33.5	95.6	(65.3-134.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	19.8	106.2	(65.7-162.3)	Male	5	10.5	47.8	(15.4-111.6)
Female	8	7.0	113.8	(49.0-224.3)	Female	8	8.2	97.1	(41.8-191.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	6	3.1	193.3	(70.6-420.6)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	9	10.0	89.8	(41.0-170.4)
Female	53	73.0	72.6	(54.3-94.9)	Female	11	9.1	121.2	(60.4-216.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.1	nc	(nc-nc)	Male	5	7.5	66.6	(21.5-155.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	33	30.0	110.0	(75.7-154.4)	Female	4	7.7	nc	(nc-nc)
Female	30	28.7	104.7	(70.6-149.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	4.9	nc	(nc-nc)	Male	86	80.0	107.5	(86.0-132.8)
Female	0	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	8.1	nc	(nc-nc)	Female	17	15.0	113.6	(66.2-182.0)
Female	7	5.2	135.4	(54.3-279.1)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	6	3.8	157.8	(57.6-343.6)
Female	1	0.9	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	4	6.1	nc	(nc-nc)	Male	60	37.7	159.3	(121.5-205.0)
Female	3	4.9	nc	(nc-nc)	Female	27	34.0	79.4	(52.3-115.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	75	54.4	138.0	(108.5-172.9)	Male	13	29.9	43.5	(23.1-74.3)
Female	29	21.0	138.3	(92.6-198.6)	Female	21	25.9	81.1	(50.2-123.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	10.8	83.0	(37.9-157.5)	Male	9	7.9	113.7	(51.9-215.8)
Female	7	9.9	70.5	(28.2-145.2)	Female	9	6.8	131.6	(60.0-249.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	28	28.6	98.0	(65.1-141.6)
Female	214	216.2	99.0	(86.2-113.2)	Female	29	27.6	105.2	(70.5-151.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	9.9	50.5	(16.3-117.9)	Male	27	20.7	130.2	(85.8-189.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	81	82.5	98.2	(77.9-122.0)	Female	18	23.0	78.2	(46.3-123.7)
Female	89	86.6	102.7	(82.5-126.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	18	15.6	115.6	(68.5-182.7)
Male	14	13.5	103.5	(56.5-173.6)	Female	18	18.3	98.4	(58.3-155.6)
Female	7	4.1	169.3	(67.8-348.9)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	232	218.8	106.0	(92.8-120.6)
Male	3	4.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	4.4	nc	(nc-nc)	Male	22	13.9	158.2	(99.1-239.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	12	9.2	130.8	(67.5-228.5)
Male	31	22.7	136.4	(92.7-193.7)	<b><u>Testis</u></b>				
Female	19	15.4	123.4	(74.2-192.7)	Male	7	9.1	77.0	(30.9-158.7)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	20	9.5	211.3	(129.0-326.3)	Male	3	6.2	nc	(nc-nc)
Female	5	2.7	183.7	(59.2-428.6)	Female	24	21.3	112.9	(72.3-168.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	14	17.6	79.7	(43.5-133.7)	Female	41	43.5	94.2	(67.6-127.8)
Female	19	15.7	121.2	(72.9-189.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	812	731.8	111.0	(103.5-118.9)
Male	9	10.5	85.6	(39.0-162.4)	Female	727	731.0	99.5	(92.4-107.0)
Female	3	4.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	136	103.5	131.4	(110.2-155.4)					
Female	107	99.5	107.5	(88.1-129.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	7.3	68.5	(22.1-159.8)	Male	6	4.1	146.2	(53.4-318.2)
Female	1	2.5	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	18	26.4	68.2	(40.4-107.8)	Female	4	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	13	11.2	115.9	(61.6-198.1)	Female	4	2.8	nc	(nc-nc)
Female	10	10.2	98.5	(47.1-181.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	39	30.4	128.3	(91.2-175.4)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	3.2	nc	(nc-nc)	Female	8	5.3	151.2	(65.1-298.0)
Female	4	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	20	14.1	141.6	(86.5-218.7)
Female	2	1.8	nc	(nc-nc)	Female	18	11.8	151.9	(90.0-240.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	27.7	104.9	(70.2-150.6)	Male	16	16.1	99.7	(56.9-161.8)
Female	14	9.7	144.6	(79.0-242.6)	Female	17	13.3	128.1	(74.6-205.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.8	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	6	5.0	120.5	(44.0-262.3)	Female	3	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	18	15.1	119.5	(70.8-188.9)
Female	103	112.5	91.6	(74.8-111.1)	Female	14	13.1	106.8	(58.3-179.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.3	170.5	(77.8-323.7)	Male	12	11.6	103.4	(53.4-180.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	37	42.6	86.8	(61.1-119.6)	Female	9	11.7	77.1	(35.2-146.4)
Female	55	38.9	141.5	(106.6-184.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	8.1	111.2	(50.7-211.1)
Male	5	7.2	69.0	(22.2-161.0)	Female	4	8.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	118	119.2	99.0	(81.9-118.5)
Male	6	2.5	235.7	(86.1-513.0)	<b><u>Stomach</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	2	7.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	4.0	125.0	(40.3-291.8)
Male	14	12.4	113.3	(61.9-190.2)	<b><u>Testis</u></b>				
Female	8	7.6	105.3	(45.3-207.5)	Male	9	4.7	190.6	(87.0-361.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	5.1	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	10	11.4	88.1	(42.2-162.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	9.1	87.9	(37.8-173.1)	Female	22	23.0	95.6	(59.9-144.7)
Female	9	7.3	123.9	(56.5-235.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	398	388.0	102.6	(92.8-113.2)
Male	12	5.7	208.9	(107.8-364.8)	Female	396	360.0	110.0	(99.4-121.4)
Female	1	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	76	54.0	140.9	(111.0-176.3)					
Female	65	48.2	134.9	(104.1-172.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	7	2.3	298.5	(119.6-615.1)
Female	2	2.0	nc	(nc-nc)	Female	6	2.1	281.3	(102.7-612.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	22	19.1	115.1	(72.1-174.3)	Female	1	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	6.8	73.7	(23.8-172.1)	Female	2	2.0	nc	(nc-nc)
Female	6	8.2	72.8	(26.6-158.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	1.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	28	17.3	162.1	(107.7-234.3)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	2	1.8	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	2	1.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	0.9	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	13	8.4	155.0	(82.4-265.0)	Male	78	58.4	133.6	(105.6-166.7)
Female	11	9.2	119.2	(59.4-213.2)	Female	72	65.6	109.7	(85.9-138.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					<b><u>Female</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	5	8.4	59.8	(19.3-139.6)
Female	0	0.6	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.9	nc	(nc-nc)	Male	5	4.1	121.6	(39.2-283.8)
Female	2	2.6	nc	(nc-nc)	Female	5	3.1	162.4	(52.3-379.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	5	1.2	419.2	(135.1-978.2)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	27	27.7	97.4	(64.2-141.7)	Female	5	3.4	148.6	(47.9-346.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	12.0	66.9	(28.8-131.8)	Female	7	2.9	241.4	(96.7-497.3)
Female	19	10.6	179.1	(107.8-279.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	42	32.1	130.9	(94.3-176.9)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	3.3	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	12	15.1	79.5	(41.1-138.9)
Female	4	1.9	nc	(nc-nc)	Female	7	12.6	55.8	(22.3-114.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	5.9	135.3	(58.3-266.7)	Male	3	4.1	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	32	29.0	110.3	(75.4-155.7)	Female	1	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	9.5	83.9	(36.1-165.3)	Female	4	2.9	nc	(nc-nc)
Female	6	8.7	69.1	(25.2-150.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	1.8	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	34	26.1	130.3	(90.2-182.1)
Male	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.9	nc	(nc-nc)
Male	6	3.0	197.7	(72.2-430.3)	<b><u>Testis</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.2	nc	(nc-nc)	Female	8	5.6	144.1	(62.0-283.9)
Female	0	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	93	89.2	104.2	(84.1-127.7)
Male	1	1.5	nc	(nc-nc)	Female	79	88.0	89.8	(71.1-111.9)
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	14	11.8	119.1	(65.0-199.8)					
Female	8	10.6	75.2	(32.4-148.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	3.2	158.4	(51.0-369.6)	Male	1	1.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	7	1.2	577.5	(231.4-1190.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	12	11.1	108.2	(55.8-189.0)	Female	0	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	4.8	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	5	4.0	125.2	(40.3-292.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.9	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	16	12.7	125.5	(71.7-203.8)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.9	nc	(nc-nc)	Female	5	2.3	217.0	(69.9-506.5)
Female	1	0.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	50	41.3	121.0	(89.8-159.6)
Male	0	0.6	nc	(nc-nc)	Female	44	35.6	123.7	(89.9-166.1)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	9	6.0	150.2	(68.5-285.1)					
Female	5	4.9	101.2	(32.6-236.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	7.0	185.0	(98.4-316.3)	Male	1	4.8	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	1.9	264.1	(85.1-616.4)	Male	1	1.1	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	29	33.1	87.7	(58.7-125.9)	Female	7	3.6	193.9	(77.7-399.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	5	3.4	147.0	(47.4-343.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	11.2	98.3	(49.0-175.9)	Female	4	3.4	nc	(nc-nc)
Female	15	9.9	151.4	(84.7-249.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	2.1	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	6	2.0	293.5	(107.2-638.9)
Female	1	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	37	30.3	122.0	(85.9-168.2)
Male	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.0	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.7	nc	(nc-nc)	Female	6	6.4	93.7	(34.2-203.9)
Female	6	2.1	280.9	(102.6-611.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	123	104.4	117.8	(97.9-140.6)
Male	3	1.7	nc	(nc-nc)	Female	109	101.3	107.6	(88.4-129.8)
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	20	13.9	144.3	(88.1-222.9)					
Female	14	12.3	114.1	(62.3-191.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.0	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	0	1.1	nc	(nc-nc)	Female	3	8.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	6.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	23	19.7	116.5	(73.8-174.8)	Female	2	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	7.0	85.5	(31.2-186.1)	Female	3	2.0	nc	(nc-nc)
Female	10	7.0	143.4	(68.7-263.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	20	19.0	105.4	(64.4-162.8)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	2.1	237.7	(76.6-554.7)	Female	5	3.8	130.7	(42.1-305.1)
Female	0	1.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	9	8.7	103.7	(47.3-196.8)
Female	2	1.4	nc	(nc-nc)	Female	8	8.1	98.8	(42.5-194.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	8.9	202.0	(119.7-319.3)	Male	3	5.4	nc	(nc-nc)
Female	6	3.4	174.4	(63.7-379.5)	Female	3	4.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.1	178.2	(81.3-338.2)
Female	43	38.7	111.1	(80.4-149.7)	Female	5	4.7	106.7	(34.4-249.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	13.8	123.5	(71.9-197.8)	Female	3	4.0	nc	(nc-nc)
Female	19	14.1	134.8	(81.1-210.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	2.6	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	Female	5	3.0	168.5	(54.3-393.1)
Female	1	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	42	36.9	113.8	(82.0-153.8)
Male	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	1.5	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.1	nc	(nc-nc)	Female	9	7.6	118.7	(54.2-225.3)
Female	2	2.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	149	125.0	119.2	(100.8-139.9)
Male	2	1.9	nc	(nc-nc)	Female	140	126.4	110.7	(93.1-130.7)
Female	2	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	26	17.3	150.7	(98.4-220.8)					
Female	18	16.6	108.6	(64.3-171.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	27.6	76.1	(47.1-116.3)	Male	19	14.8	128.1	(77.1-200.0)
Female	12	11.0	109.4	(56.5-191.1)	Female	15	12.8	117.6	(65.8-194.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	8	4.0	200.0	(86.1-394.1)
Female	4	4.9	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	20	14.2	141.1	(86.2-218.0)
Female	105	109.6	95.8	(78.3-115.9)	Female	15	14.1	106.2	(59.4-175.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.8	145.4	(58.3-299.6)	Male	4	10.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	34	41.8	81.4	(56.4-113.7)	Female	15	11.7	128.5	(71.9-212.0)
Female	48	45.8	104.9	(77.3-139.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	7.9	126.9	(60.7-233.4)
Male	6	6.8	88.1	(32.2-191.8)	Female	8	9.7	82.8	(35.7-163.2)
Female	1	2.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	132	109.5	120.6	(100.9-143.0)
Male	1	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	6	7.0	85.2	(31.1-185.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	4.9	nc	(nc-nc)
Male	11	11.4	96.8	(48.3-173.3)	<b><u>Testis</u></b>				
Female	6	7.9	76.4	(27.9-166.3)	Male	3	4.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	4.7	nc	(nc-nc)	Male	6	3.0	201.7	(73.6-439.0)
Female	1	1.4	nc	(nc-nc)	Female	16	10.0	159.8	(91.3-259.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	8.6	127.7	(63.7-228.5)	Female	20	21.9	91.5	(55.9-141.3)
Female	11	8.0	138.3	(69.0-247.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	372	366.2	101.6	(91.5-112.5)
Male	7	5.3	131.9	(52.8-271.7)	Female	366	373.3	98.0	(88.3-108.6)
Female	2	2.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	36	52.3	68.8	(48.2-95.2)					
Female	40	51.2	78.2	(55.8-106.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	7	6.4	110.2	(44.2-227.1)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	2.2	nc	(nc-nc)	Female	3	0.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	6.4	171.5	(85.5-306.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	5	2.7	183.5	(59.1-428.3)
Female	0	0.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;